, one of the most influential advocacy groups in the country, is ‘still optimistic about the President acting on cannabis reform’. ){kind=link}
The US Cannabis Roundtable (USCR), one of the most influential advocacy groups in the country, is ‘still optimistic about the President acting on cannabis reform’.
Talking to Green Market Report David Culver (USCR Senior Vice-President of Public Affairs) believes the current speculation regarding the demise of the process of rescheduling that began under Biden’s administration is premature.
Despite growing evidence that the DEA has moved to undermine the process, and plenty of investigation into the attitudes towards cannabis of the new administration, Culver believes the ultimate decision will lie with the President, and that the industry ‘is going to have to wait our turn’.
With the process currently stuck in limbo pending the conclusion of an interlocutory appeal into the DEA’s neutrality, the ‘ball remains in the DEA’s court’ for now.
Culver said that Trump puts loyalty before all else, and anyone who strays away from his line of thinking on important issues will be immediately dismissed. He also suggested that neutrality by key officials in regards to cannabis is not a cause for concern.
Culver noted that there are a number of administration officials, including key ones, who are “very procannabis” reform.
He added that he remained confident the President ‘has evolved on this issue considerably since he was in office last time around’, but that cannabis reform simply was not a priority for the first months of the administration.
“I think that (the DEA are) going to need to get direction from the President in order for rescheduling to occur… The big question is when.”
It comes just weeks after controversial former congressman and Trump loyalist Matt Gaetz suggested in an op-ed that cannabis rescheduling could be ‘on the horizon’.
The DEA also reported last week that there had been no further progress made in the rescheduling cases since the suspension.
In a status report submitted to Administrative Law judge John J. Mulrooney on April 10, DEA lawyers stated that acting administrator Derek Maltz had not yet set a schedule for briefings that would have allowed parties to formally argue on whether or not the DEA could continue to act as the promoter of the rule-change.
In the Office of National Drug Control Policy’s list of policy priorities for 2025, cannabis reform or rescheduling was not mentioned. This further fuels concerns about the administration’s stance on the matter.
Lawyers have suggested that the movants may ultimately seek intervention from the DC Circuit Court, arguing that the DEA’s failure to act constitutes an ‘unreasonable delay’ under the Administrative Procedure Act.
The US Cannabis Roundtable (USCR), one of the most influential advocacy groups in the country, is ‘still optimistic about the President acting on cannabis reform’.
Talking to Green Market Report David Culver (USCR Senior Vice-President of Public Affairs) believes the current speculation regarding the demise of the rescheduling procedure, started by the Biden Administration, is premature.
Despite growing evidence that the DEA has moved to undermine the process, and plenty of investigation into the attitudes towards cannabis of the new administration, Culver believes the ultimate decision will lie with the President, and that the industry ‘is going to have to wait our turn’.
With the process currently stuck in limbo pending the conclusion of an interlocutory appeal into the DEA’s neutrality, the ‘ball remains in the DEA’s court’ for now.
Culver said that Trump puts loyalty before all else, and anyone who strays away from his line of thinking on important issues will be immediately dismissed. He also suggested that neutrality by key officials in regards to cannabis is not a cause for concern.
Culver stated that “there are a number of administration officials who are pro-cannabis reform”.
He added that he remained confident the President ‘has evolved on this issue considerably since he was in office last time around’, but that cannabis reform simply was not a priority for the first months of the administration.
“I think that (the DEA are) going to need to get direction from the President in order for rescheduling to occur… The big question is when.”
It comes just weeks after controversial former congressman and Trump loyalist Matt Gaetz suggested in an op-ed that cannabis rescheduling could be ‘on the horizon’.
However, the DEA also reported last week that there had been no further progress made in the rescheduling cases since the suspension.
In a jointly submitted status update on April 10th to Administrative Law Judge John J. Mulrooney by DEA attorneys, it was stated that acting administrator Derek Maltz still has not set a timetable for briefings which would enable parties to formally argue on whether the DEA is allowed to remain as proponent of rule change.
In the Office of National Drug Control Policy’s list of policy priorities for 2025, cannabis reform or rescheduling was not mentioned. This further fuels concerns about the administration’s stance on the matter.
Lawyers have suggested that the movants may ultimately seek intervention from the DC Circuit Court, arguing that the DEA’s failure to act constitutes an ‘unreasonable delay’ under the Administrative Procedure Act.
Cannabis Law Resources in Poland
Browse essential legal pages on cannabis sales and cultivation in Poland. These guides will help you understand the legal requirements, such as certifications and permissions.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland